Introduction {#s2}
============

Asthma is a highly prevalent condition that currently ranks as the third most prevalent chronic disease in children, and is estimated to affect 7.1 million US children under the age of 18 y [@pmed.1001753-Centers1]. Furthermore, asthma is the third leading cause of hospitalization among US children under the age of 15 y [@pmed.1001753-Centers2], and in 2010 alone, there were approximately 640,000 pediatric emergency room visits related to asthma [@pmed.1001753-Centers3]. The consequences of asthma are further illustrated by the inordinately elevated annual direct health care costs of pediatric asthma, which amount to approximately US\$50.1 billion in the US, with an additional indirect cost of US\$5.9 billion attributable to lost productivity related to missed school days and, secondarily, missed work days for parents [@pmed.1001753-Barnett1].

The mainstay of asthma control is adherent daily administration of anti-inflammatory therapies, including inhaled corticosteroids, inhaled corticosteroids combined with long-acting β~2~ agonists, and leukotriene receptor antagonists. Other important aspects aiming to optimize asthma control include avoidance of asthma triggers such as seasonal allergens and environmental pollution, particularly tobacco smoke exposure. However, recent studies have found asthma to be associated with several frequently overlapping co-morbidities including gastroesophageal reflux [@pmed.1001753-Blake1],[@pmed.1001753-Harding1], obesity [@pmed.1001753-FigueroaMunoz1]--[@pmed.1001753-Gennuso1], and sleep-disordered breathing [@pmed.1001753-Desager1]--[@pmed.1001753-KheirandishGozal2], and have introduced plausible therapeutic strategies aimed at improving asthma control by minimizing or completely eradicating the burden of these coexisting conditions.

Obstructive sleep apnea (OSA) is considered the most prevalent and severe entity within the spectrum of sleep-disordered breathing, and affects approximately 2%--3% of all children [@pmed.1001753-Ali1]--[@pmed.1001753-MontgomeryDowns1]. Similar to asthma, the cardinal pathophysiological feature associated with childhood OSA involves the presence of increased airway inflammation, promoting the hypertrophy of upper airway adenotonsillar tissues [@pmed.1001753-Marcus1]--[@pmed.1001753-Kim1]. The latter, either alone or in combination with other craniofacial and neuromuscular factors, promotes the presence of increased pharyngeal resistance. Thus, when the expected loss of the physiological dilator reflexes of the upper airway develops during sleep, these hypertrophic tissues and their underlying inflammatory components predispose the upper airway to episodically collapse, and cause the gas exchange abnormalities and fragmented sleep that characterize OSA [@pmed.1001753-Arens1]. Moreover, the repetitive upper airway obstruction during sleep and accompanying intermittent hypoxemia and hypercapnia, recurrent cortical microarousals, and sympathetic nervous system activation trigger oxidative stress and systemic inflammatory pathways that are currently believed to mediate OSA-associated morbidities [@pmed.1001753-Bhattacharjee1]. Consequently, surgical adenotonsillectomy (AT) is considered the first line of therapy in childhood OSA and has recently shown overall favorable outcomes, including substantial improvements in the severity of respiratory sleep disturbances [@pmed.1001753-Marcus2]--[@pmed.1001753-Marcus3] and in reducing markers of OSA-associated systemic inflammation [@pmed.1001753-Gozal1]. As anticipated, secular trends have revealed an increased frequency of AT in children over the past two decades related to a higher prevalence of obstructive breathing [@pmed.1001753-Erickson1], although rarely is a formal diagnosis of OSA established through polysomnography by most otolaryngologists before AT [@pmed.1001753-Mitchell1].

Recent evidence has suggested that the pathophysiological complications of asthma and OSA may overlap in children, supporting the "united airway hypothesis" [@pmed.1001753-Gozal2]. Numerous survey-based studies have reported a strong severity-dependent association between OSA and symptoms of asthma [@pmed.1001753-Desager1],[@pmed.1001753-Verhulst1]--[@pmed.1001753-Chng1]. Moreover, in a single-center cohort study of children with asthma, AT for those children who had polysomnographic evidence of OSA reduced the frequency of asthma exacerbations and of bronchodilator usage, and led to substantial improvements in pulmonary function [@pmed.1001753-KheirandishGozal1]. However, to our knowledge, a systematic examination of the association of AT with asthma outcomes in a large sample of children has never been performed. To that end, we employed the MarketScan database, which contains a large longitudinal cohort of children with private health insurance, and extracted all those children with asthma diagnostic codes and asthma-specific pharmacy reimbursements. We examined the frequency of specific asthma outcomes before and after AT. Further, we compared these outcomes with matched children with asthma who did not undergo AT in order to evaluate the natural history of asthma over time [@pmed.1001753-Ko1]. We hypothesized that removal of the adenoids and tonsils, thereby improving sleep-disordered breathing and plausibly eradicating OSA, would be associated with substantial improvements in asthma control.

Methods {#s3}
=======

Ethics Statement {#s3a}
----------------

This study was approved by the University of Chicago\'s Institutional Review Board (BSD/UCH IRB approval no. 10-567-E).

Data Source {#s3b}
-----------

All data were obtained using the MarketScan database, which provides access to a large database of over 180 million patients with private health insurance since 1995, including a large cohort of children (\>25 million children). The MarketScan database collects payment information, capturing reimbursements from the health insurance plans and payments accrued by patients. It provides access to integrated patient-level data on expenses using billable codes in both the inpatient and outpatient settings, and also includes access to patient-level pharmacy expenses. Children were identified for a study period between January 1, 2003, and December 31, 2010.

Participant Selection {#s3c}
---------------------

Children aged 3 to 17 y with asthma were identified from the MarketScan database using asthma-specific International Classification of Diseases, Ninth Revision--Clinical Modification (ICD-9-CM) codes of asthma (493.XX). From this cohort, all children with asthma who had undergone AT were identified using current procedural terminology (CPT) codes specific for AT (CPT for AT for children aged \<12 y is 42820, and for AT for children aged \>12 y is 42821). Our cases (AT+) served as their own controls for the 1 y preceding AT. In addition, we studied a second group of matched children with asthma who did not undergo AT (AT−). These children were chosen if they met the above criteria for asthma, but did not have a history of any CPT codes for AT, adenoidectomy, or tonsillectomy. The purpose of adding this group was to include a cohort of children with asthma from the database in order to characterize the natural history of asthma when there is no confounding influence of complications related to adenotonsillar hypertrophy. This is of particular relevance since asthma severity improves with age, and recent evidence advocates the inclusion of a control group of children with asthma in studies examining the efficacy of an intervention in asthma [@pmed.1001753-Ko1]. AT− children were matched using a 2∶1 ratio to AT+ children, and were selected using a greedy selection algorithm according to age, sex, home location (urban or rural), and geographical state of residence based on a macro employed by SAS software, version 9.3. The greedy algorithm selects matched controls based on selecting the next ideal match in the fewest steps, without spanning the entire database to choose the best match.

Because of the technical and ethical constraints of the MarketScan database, the dataset does not contain information on ethnicity or obesity status. In both AT+ and AT− children, the presence of ICD-9-CM codes corresponding to any confounding disease that could influence the respiratory tract and/or affect the efficacy of AT in the treatment of sleep-disordered breathing led to exclusion ([Figure 1](#pmed-1001753-g001){ref-type="fig"}).

![Selection of children from the MarketScan database following exclusion of specific comorbidities.\
Both AT+ and AT− children had to have data for 1 y prior to and 1 y after the index date (AT surgery or January 1) to be included. AT+ children were selected if they had an identified diagnostic code for asthma and AT. Matched AT− children were selected according to a 2∶1 ratio to AT+ children using a greedy selection algorithm. AT− children had a code for asthma without an identified diagnostic code for AT, adenoidectomy, or tonsillectomy. SMA, spinal muscular atrophy.](pmed.1001753.g001){#pmed-1001753-g001}

After implementation of the stringent selection criteria to form our study population, the temporal nature of study outcomes was entirely based on the timing of AT. For children with asthma who had undergone AT (AT+), the frequency of outcomes was examined during 1 y prior to the AT date and compared to during 1 y following the AT date. In children with asthma without a history of AT (AT−), the frequency of outcomes was examined over a similar 2-y period, such that AT− children had the same age, sex, home location, and geographical state as AT+ children at the time of AT, with the frequency of outcomes being defined as during the 1 y before and the 1 y after the arbitrary date of January 1. We examined a 2-y time period (1 y pre-AT and 1 y post-AT for AT+ children, and first and second year of follow-up for AT− children) in order to capture the frequency of asthma events over all four seasons. Of note, longer follow-up periods incurred a greater probability that children would drop out because of incomplete follow-up time or a higher likelihood that children would change health insurance providers. A clear limitation of the MarketScan database is that in the event that a child changes health insurance coverage, a new identification code is created, such that under these circumstances one child might be included as two separate children instead of one. Therefore, AT+ children without 1 y of pre-AT and 1 y of post-AT data and AT− children without 2 y of data under the same identification code were not included. Finally, only children from the continental United States and Alaska were included (i.e., children from Hawaii, Puerto Rico, Guam, and the US Virgin Islands were excluded).

Study Outcomes {#s3d}
--------------

The primary outcomes for the present study were the frequency of ICD-9-CM codes ([Table S1](#pmed.1001753.s003){ref-type="supplementary-material"}) for acute asthma exacerbation (AAE) and acute status asthmaticus (ASA). Secondary outcomes included the frequency of additional surrogates of asthma status such as ICD-9-CM codes ([Table S1](#pmed.1001753.s003){ref-type="supplementary-material"}) for acute bronchospasm and wheezing, and CPT codes for spirometry, intubation, and initiation of "continuous inhalation for the first hour," which would suggest an asthma exacerbation requiring continuous bronchodilator therapy, as is commonly performed in the emergency room setting.

In addition, since the MarketScan database provided outpatient pharmacy reimbursement claims in 10,663 AT+ children (79%) and 21,023 AT− children (78%), an additional secondary outcome was the frequency of asthma-specific outpatient medication prescription reimbursement ([Table S2](#pmed.1001753.s004){ref-type="supplementary-material"}) during the same periods. For systemic corticosteroids we searched the database for generic and brand names of oral forms (tablet, syrup, elixir) of prednisone and prednisolone.

Finally, we examined all asthma-related emergency room visits (ARERs) and asthma-related hospitalizations (ARHs) by screening emergency room visits and hospitalizations in which the primary or secondary diagnostic code was billed for AAE or ASA ([Table S1](#pmed.1001753.s003){ref-type="supplementary-material"}) or acute bronchospasm or wheezing (CPT codes).

Statistical Analysis {#s3e}
--------------------

Demographic data between AT+ and AT− children were compared using one-way ANOVA for age and chi-square for categorical outcomes. In the setting of multiple variables, such as in home location, a Wilcoxon matched-pairs signed rank test was used to compare AT+ to AT− children.

We used Fisher\'s exact test or chi-square with Yates\' correction if the sample size was particularly large to compare the frequency of outcomes between AT+ and AT− children. Confidence intervals of proportions of a population were determined using a Wilson score interval.

Results {#s4}
=======

For the study period January 1, 2003, to December 31, 2010, we identified 1,733,278 million children with asthma of a total of 23,340,142 million enrollees (ages 3--17 y) available in the database (prevalence of 7.4%) ([Figure 1](#pmed-1001753-g001){ref-type="fig"}). Following exclusion of co-morbidities, we identified 51,794 children who had both an ICD-9-CM code for asthma and had undergone AT. Inclusion of children that had 1 y of data both pre- and post-AT reduced the number of AT+ children to 13,506 ([Figure 1](#pmed-1001753-g001){ref-type="fig"}). Children excluded from the AT+ group because of insufficient follow-up data or because they did not reside in the continental United States did not markedly differ from children included in the AT+ group in distribution of age, gender, home location, and availability of pharmacy reimbursement claims. There were, however, observed differences in diagnostic codes provided for AT ([Table S3](#pmed.1001753.s005){ref-type="supplementary-material"}). Following exclusion of co-morbidities, 932,606 candidate AT− children that fulfilled the 2-y follow-up requirement were identified from the database. Using a greedy selection algorithm with a target ratio of two AT− children for each AT+ child provided 27,012 AT− children who were successfully matched to AT+ children for age ([Figure S1](#pmed.1001753.s002){ref-type="supplementary-material"}), sex, home location ([Table 1](#pmed-1001753-t001){ref-type="table"}), and geographical state of residence. Only the diagnostic codes of adenotonsillar hypertrophy, adenotonsillitis, sleep apnea, snoring, and sleep disturbance were significantly higher in the AT+ group ([Table 1](#pmed-1001753-t001){ref-type="table"}).

10.1371/journal.pmed.1001753.t001

###### Demographic summary of case (adenotonsillectomy) and control populations.

![](pmed.1001753.t001){#pmed-1001753-t001-1}

  Characteristic                                                                                                                                       AT+ Group     AT− Group (2∶1 Match)   *p*-Value
  ------------------------------------------------------------------------------------------------------------------------------------------------- --------------- ----------------------- -----------
  **Number of children**                                                                                                                                13,506              27,012          
  [**Diagnostic code**]{.ul}                                                                                                                                                                
  474.1× (hypertrophy of tonsils and adenoids)                                                                                                        5,942 (44%)          537 (2%)          \<0.0001
  474.0× (chronic tonsillitis and adenoiditis)                                                                                                        3,062 (23%)         137 (0.5%)         \<0.0001
  474.1×, 474.0× (hypertrophy of tonsils and adenoids and chronic tonsillitis and adenoiditis)                                                        2,344 (17%)          265 (1%)          \<0.0001
  327.20, 327.23, 327.24, 327.26, 327.29, 780.51, 780.53, 780.57, 786.03, 780.50, 780.56, 780.59 (sleep apnea, snoring, and/or sleep disturbance)     3,603 (27%)         1,099 (1%)         \<0.0001
  **Age in years, mean ± standard deviation**                                                                                                          7.70±3.65           7.68±3.66           0.49
  **[Gender]{.ul}**                                                                                                                                                                         
  Male                                                                                                                                                7,440 (55%)        14,880 (55%)          1.00
  Female                                                                                                                                              6,066 (45%)        12,132 (45%)       
  **With available pharmacy reimbursement claims**                                                                                                   10,663 (79%)        21,023 (78%)          1.00
  **[Home location]{.ul}**                                                                                                                                                                     0.98
  **Metropolitan counties**                                                                                                                                                                 
  Counties in metro areas of 1 million population or more                                                                                            6,116 (45.2%)      12,249 (45.3%)      
  Counties in metro areas of 250,000--1,000,000 population                                                                                           2,746 (20.3%)       6,088 (22.5%)      
  Counties in metro areas of fewer than 250,000 population                                                                                           1,896 (14.0%)       3,597 (13.3%)      
  **Nonmetropolitan counties**                                                                                                                                                              
  Urban population of 20,000 or more, adjacent to a metro area                                                                                        756 (5.6%)         1,463 (5.4%)       
  Urban population of 20,000 or more, not adjacent to a metro area                                                                                    278 (2.1%)          607 (2.2%)        
  Urban population of 2,500--19,999, adjacent to a metro area                                                                                        1,024 (7.6%)        1,751 (6.5%)       
  Urban population of 2,500--19,999, not adjacent to a metro area                                                                                     442 (3.3%)          846 (3.1%)        
  Completely rural or urban population of less than 2,500, adjacent to a metro area                                                                   124 (0.9%)          222 (0.8%)        
  Completely rural or urban population less than 2,500, not adjacent to a metro area                                                                  124 (0.9%)          189 (0.7%)        

Values are number (percent) unless otherwise stated. *p*-Value is for the difference between the two groups.

The frequency of episodes of AAE and ASA declined significantly in AT+ children following AT, while such frequency only slightly decreased in AT− children between the first year and the second year of follow-up. Indeed, the frequency of AAE was reduced from 2,243 pre-AT to 1,566 post-AT in the AT+ children, as compared to 3,403 in the first year and 3,336 in the second year in AT− children (30% versus 2% relative risk reduction; *p*\<0.0001; [Table 2](#pmed-1001753-t002){ref-type="table"}). Similarly, the frequency of ASA decreased in AT+ children from 562 pre-AT to 349 post-AT, as compared to 837 in the first year and 778 in the second year in AT− children (38% versus 7% relative risk reduction; *p*\<0.0001) ([Table 2](#pmed-1001753-t002){ref-type="table"}). When comparing each primary outcome individually, significant reductions associated with AT occurred in nearly all outcomes ([Table S1](#pmed.1001753.s003){ref-type="supplementary-material"}). When the number of episodes was normalized per 1,000 children, the frequency of AAE and ASA was higher in children in the AT+ group prior to AT than in the AT− group in the first year of follow-up ([Figure 2A and 2B](#pmed-1001753-g002){ref-type="fig"}). However, in the 1 y following AT, the frequency of AAE and ASA in AT+ children reached levels similar to those of AT− children in the second year of follow-up. The overall reductions in AAE and ASA (i.e., post-AT 1 y minus pre-AT 1 y) among AT+ children were present across the age spectrum ([Figure 2C and 2D](#pmed-1001753-g002){ref-type="fig"}).

![Annual incidence of primary asthma outcomes (acute asthma exacerbation and acute status asthmaticus).\
Annual incidence of AAE (A) and ASA (B) expressed per 1,000 children. Red bars represent 1 y prior to AT in AT+ children or the first year of follow-up in AT− children; green bars represent 1 y after AT or the second year of follow-up. The difference in annual incidence of AAE (C) and ASA (D) is calculated by subtracting the incidence during 1 y pre-AT (or first year of follow-up in AT− children) from the incidence during 1 y post-AT (or second year of follow-up in AT− children). Black circles represent the AT+ group, and white squares represent the AT− group. All error bars represent the 95th percentile confidence intervals for a sample proportion.](pmed.1001753.g002){#pmed-1001753-g002}

10.1371/journal.pmed.1001753.t002

###### Annual incidence of acute asthma exacerbation and acute status asthmaticus: comparing adenotonsillectomy to no adenotonsillectomy.

![](pmed.1001753.t002){#pmed-1001753-t002-2}

  Item                                AAE                     ASA                                    
  ------------------------- ------------------------ ---------------------- ------------------------ -----------------------
  1 y pre-AT/first year              2,243                   3,403                    562                      837
  1 y post-AT/second year            1,566                   3,336                    349                      778
  Percent reduction          30.0% (25.6% to 34.3%)   2.0% (−2.5% to 6.3%)   37.9% (29.2% to 45.6%)   6.8% (−2.6% to 15.4%)
  *p*-Value                                               *p*\<0.0001                                      *p*\<0.0001

Data are number or percent (95% CI). *p*-Value is for the difference between the two groups.

Additionally, there were statistically significant reductions in health care provider coding for acute bronchospasm, wheezing, spirometry usage, and continuous inhalation therapy for the first hour in AT+ children following AT relative to corresponding matched AT− children in the analogous second year of follow-up ([Table 3](#pmed-1001753-t003){ref-type="table"}; [Figure 3](#pmed-1001753-g003){ref-type="fig"}). The frequency of coding for endotracheal intubation, however, was not different between the two groups.

![Annual incidence of secondary asthma outcomes expressed per 1,000 children.\
Red bars represent 1 y pre-AT in AT+ children or first year of follow-up in AT− children; green bars represent 1 y post-AT or second year of follow-up. All error bars represent the 95th percentile confidence intervals for a sample proportion. (A) Annual incidence of billing codes for acute bronchospasm, wheezing, and intubation. (B) Annual incidence of billing codes for spirometry and continuous inhalation for first hour.](pmed.1001753.g003){#pmed-1001753-g003}

10.1371/journal.pmed.1001753.t003

###### Annual incidence of secondary asthma outcomes: comparing adenotonsillectomy to no adenotonsillectomy.

![](pmed.1001753.t003){#pmed-1001753-t003-3}

  Item                        Acute Bronchospasm           Wheezing                Spirometry         Continuous Inhalation for First Hour        Intubation                                                                                       
  ------------------------- ----------------------- ----------------------- ------------------------ -------------------------------------- ----------------------- ------------- ------------------------ ------------- ------------------------- -----------------------
  1 y pre-AT/first year               251                     448                     839                            1,222                           1,615              1,820              2,225               3,054                22                       49
  1 y post-AT/second year             188                     431                     501                            1,261                           1,398              2,471              1,563               3,251                16                       29
  Percent reduction          25.1% (9.7% to 37.9%)   3.8% (−9.7% to 15.6%)   40.3% (33.5% to 46.4%)                   0.0%                   13.4% (7.4% to 19.1%)      0.0%       30.0% (25.4% to 33.8%)      0.0%       27.2% (−38.4% to 61.8%)   40.8% (6.4% to 62.6%)
  *p*-Value                                               *p* = 0.04                                              *p*\<0.0001                                        *p*\<0.0001                            *p*\<0.0001                                  *p* = 1.00

Data are number or percent (95% CI). *p*-Value is for the difference between the two groups.

The information available on pharmacy reimbursements in the MarketScan database provides data regarding the number of prescription refills during the study period as well as the number of children filling a specific prescription. We chose to investigate both measures since in some children, particularly those with poorly controlled asthma, numerous prescriptions may have been refilled during the 2-y period. Regarding prescription refills, compared to AT− children, AT+ children having undergone AT had significant decreases in most classes of asthma prescriptions in the 1 y following AT. There was a 16.7% reduction in prescription refills for bronchodilators, a 21.5% reduction for inhaled corticosteroids, and a 13.4% reduction for leukotriene receptor antagonists ([Table 4](#pmed-1001753-t004){ref-type="table"}). However, there were no reductions in prescription refills of combination inhaled corticosteroids/long-acting β~2~ agonists, typically reserved for children with severe asthma, while in AT− children there was a 20.1% increase in the number of such prescriptions ([Table 4](#pmed-1001753-t004){ref-type="table"}).

10.1371/journal.pmed.1001753.t004

###### Annual prescriptions filled for asthma therapies: comparing adenotonsillectomy to no adenotonsillectomy.

![](pmed.1001753.t004){#pmed-1001753-t004-4}

  Item                          Bronchodilator             ICS                ICS/LABA            LTRA       Systemic Corticosteroids                                                                            
  ------------------------- ---------------------- ------------------- ---------------------- ------------- -------------------------- ------------- ---------------------- ------------- ---------------------- -------------------
  1 y pre-AT/first year             13,905               21,638                10,053            13,998               3,114                3,641             15,463            17,775              889                  1,184
  1 y post-AT/second year           11,580               21,070                7,887             14,276               3,182                4,373             13,386            18,852              678                  1,098
  Percent reduction          16.7% (16.1%--17.3%)   2.6% (2.4%--4.8%)   21.5% (20.7%--22.3%)      −2.0%               −2.2%               −20.1%      13.4% (12.9%--14.0%)      −6.1%      23.7% (20.9%--26.5%)   7.3% (5.8%--8.7%)
  *p*-Value                                            *p*\<0.0001                             *p*\<0.0001                              *p*\<0.0001                          *p*\<0.0001                             *p* = 0.003

Data are number or percent (95% CI). *p*-Value is for the difference between the two groups.

ICS, inhaled corticosteroid; LABA, long-acting β~2~ agonist; LTRA, leukotriene receptor antagonist.

Upon examination of the number of children who filled various asthma prescriptions after normalizing per 1,000 children ([Figure 4A](#pmed-1001753-g004){ref-type="fig"}), it is apparent that prior to AT, more AT+ children required prescriptions for bronchodilators, inhaled corticosteroids, and leukotriene receptor antagonists, and the number of AT+ children requiring these therapies declined to levels similar to those of AT− children following AT.

![Annual number of children using asthma-specific prescription therapies.\
(A) Annual number of children using various asthma therapies expressed per 1,000 children. Solid red bars: AT+ group 1 y pre-AT; solid green bars: AT+ group 1 y post-AT. Red striped bars: AT− group first year of follow-up; green striped bars: AT− group second year of follow-up. (B) Annual number of children using systemic corticosteroids expressed per 1,000 children. (C) The difference in the number of children filling a prescription for a bronchodilator, subtracting the number during 1 y pre-AT (or first year of follow-up in AT− group) from the number during 1 y post-AT (or second year of follow-up). Black circles represent AT+ group means, and white squares represent AT− group means. (D) The difference in the number of children filling a prescription for a systemic corticosteroid therapy, subtracting the number during 1 y pre-AT (or first year of follow-up in AT− group) from the number during 1 y post-AT (or second year of follow-up). Black circles represent AT+ group, and white squares represent AT− group. All error bars represent the 95th percentile confidence intervals for a sample proportion. BD, bronchodilator; ICS, inhaled corticosteroid; ICS/LABA, inhaled corticosteroid with long-acting β~2~ agonist; LTRA, leukotriene receptor antagonist.](pmed.1001753.g004){#pmed-1001753-g004}

The number of prescription refills of systemic corticosteroids, which could indicate an asthma exacerbation, was markedly reduced in AT+ children following AT compared to the analogous second year of follow-up in AT− children (23.7% versus 7.3% reduction; *p* = 0.003) ([Table 4](#pmed-1001753-t004){ref-type="table"}). When examining the number of children needing systemic corticosteroids after normalizing the data per 1,000 children ([Figure 4B](#pmed-1001753-g004){ref-type="fig"}), a larger proportion of AT+ children than AT− children needed systemic corticosteroids during the year prior to AT/first year of follow-up, but after AT, systemic corticosteroid use by AT+ children reached a level similar to that of AT− children in the second year of follow-up. Finally, assessment of the difference in the number of children filling a prescription for either bronchodilator or systemic corticosteroid therapies ([Figure 4C and 4D](#pmed-1001753-g004){ref-type="fig"}, respectively) from the year pre-AT to the year post-AT revealed that the reduction of bronchodilator therapy post-AT was consistently present at all ages in AT+ children, while the reduction in systemic corticosteroids in AT+ children appeared to occur mostly in children \<10 y of age.

The numbers of ARERs and ARHs were also significantly reduced following AT in AT+ children compared to AT− children in the second year of follow-up (25.6% versus 0.0% reduction; *p*\<0.0001; and 35.8% versus 12.2% reduction; *p* = 0.0025) ([Table 5](#pmed-1001753-t005){ref-type="table"}). Following normalization of the number of children per 1,000 children ([Figure 5](#pmed-1001753-g005){ref-type="fig"}), the frequency of severe asthma as related to the frequency of ARERs and ARHs was higher in AT+ children pre-AT and improved to levels comparable to those of AT− children following AT.

![Annual frequency of asthma-related emergency room visits and asthma-related hospitalizations expressed per 1,000 children.\
(A) ARERs and (B) ARHs. Red bars represent 1 y prior to AT in the AT+ group and the first year of follow-up in the AT− group; green bars represent 1 y post-AT in the AT+ group and the second year of follow-up in the AT− group. All error bars represent the 95th percentile confidence intervals for a sample proportion.](pmed.1001753.g005){#pmed-1001753-g005}

10.1371/journal.pmed.1001753.t005

###### Annual frequency of asthma-related emergency room visits and asthma-related hospitalizations: comparing adenotonsillectomy to no adenotonsillectomy.

![](pmed.1001753.t005){#pmed-1001753-t005-5}

  Item                               ARERs               ARHs                               
  ------------------------- ------------------------ ------------- ------------------------ ------------------------
  1 y pre-AT/first year               712                 977                193                      375
  1 y post-AT/second year             530                1,056               124                      329
  Percent reduction          25.6% (16.9% to 33.3%)      0.0%       35.8% (19.6% to 48.7%)   12.3% (−1.6% to 24.3%)
  *p*-Value                                           *p*\<0.0001                                 *p* = 0.0247

Data are number or percent (95% CI). *p*-Value is for the difference between the two groups.

Discussion {#s5}
==========

In this large sample of privately insured children with asthma, we examined longitudinal data and found that in children with asthma but without other significant comorbidities, AT was associated with significant decreases in asthma exacerbations as well as reductions in asthma-specific medication refills. The rationale of the current study was to examine whether the proposed overlap of two commonly inflammatory conditions in children, namely, asthma and OSA, leads to interdependent effects on the severity of the disease. To purposefully address our objective, we assumed that the primary indication for AT among most children in this cohort is for symptoms of OSA, and substantial evidence supports this assumption [@pmed.1001753-Erickson1]. Accordingly, current findings support the possibility that the presence of OSA aggravates underlying asthma in children, and that treatment of OSA (via AT) might ameliorate the severity of asthma and reduce the need for more intensive use of anti-asthmatic medications. However, prospective trials are necessary to establish a causal relationship.

Before we discuss the potential implications of the current findings, some methodological issues deserve comment. We believe that the use of AT CPT codes provides a reasonably reliable surrogate indicator for the presence of OSA, particularly considering that during the period covered in the study, the vast majority of ATs were performed as treatment for OSA [@pmed.1001753-Erickson1]. We deliberately used CPT codes for AT instead of ICD-9-CM codes for OSA. A priori evaluation of our AT+ and AT− children revealed that only 842 (6.2%) of the AT+ children and 159 (0.6%) of the AT− children had undergone some form of evaluation for sleep-disordered breathing as determined by searching for specific sleep diagnostic testing CPT codes ([Table S4](#pmed.1001753.s006){ref-type="supplementary-material"}). This observation is consistent with previous studies indicating that the vast majority of children undergoing AT are unlikely to undergo formal diagnostic polysomnography testing for OSA [@pmed.1001753-Weatherly1],[@pmed.1001753-Friedman1]. In order to capture the large population of children with OSA treated with AT in whom diagnostic testing was not conducted, confirmation of OSA by concurrent utilization of the sleep diagnostic CPT codes was precluded. Given the secular trends whereby OSA is the major indication for AT in up to 80% of children [@pmed.1001753-Erickson1], we surmise that most children in our study underwent AT for symptoms of OSA. Despite the paucity of diagnostic polysomnography in the AT+ group, 27% of children did have an insurance claim for a diagnostic code of sleep apnea, snoring, or sleep disturbance, and 44% of children had an insurance claim for adenotonsillar hypertrophy during the 1-y period prior to surgery. Only 23% of children had an isolated insurance claim of chronic tonsillitis and adenoiditis ([Table 1](#pmed-1001753-t001){ref-type="table"}).

In addition, the diagnosis of asthma is particularly problematic in younger children, given their limited ability to participate in diagnostic pulmonary function testing including methacholine or exercise bronchial provocation testing. Moreover, virally induced wheezing during early childhood may often be incorrectly labeled as asthma. To partially overcome this limitation, we separately analyzed children under 6 y of age and older children ([Table 6](#pmed-1001753-t006){ref-type="table"}). The associations between AT and improvements in asthma outcomes remained essentially unchanged from analyses in which all children were included independent of age.

10.1371/journal.pmed.1001753.t006

###### Annual incidence of acute asthma exacerbation and acute status asthmaticus in children \<6 and children ≥6 y: comparing adenotonsillectomy to no adenotonsillectomy.

![](pmed.1001753.t006){#pmed-1001753-t006-6}

  Item                                AAE                      ASA                                    
  ------------------------- ------------------------ ----------------------- ------------------------ ------------------------
  **Ages 6--17 y**                                                                                    
  1 y pre-AT/first year              1,286                    2,111                    343                      490
  1 y post-AT/second year             937                     2,106                    213                      475
  Percent reduction          27.1% (21.0% to 32.8%)   0.2% (−5.7% to 5.9%)    37.9% (26.4% to 47.6%)   3.1% (−9.9% to 14.5%)
  *p*-Value                                                *p*\<0.0001                                      *p*\<0.0001
  **Ages 3--5 y**                                                                                     
  1 y pre-AT/first year               957                     1,292                    219                      347
  1 y post-AT/second year             629                     1,230                    136                      303
  Percent reduction          34.3% (27.5% to 40.4%)   4.8% (−2.7% to 11.8%)   38.2% (29.2% to 46.0%)   12.7% (−1.8% to 25.1%)
  *p*-Value                                                *p*\<0.0001                                      *p* = 0.0115

Data are number or percent (95% CI). *p*-Value is for the difference between the two groups.

Notwithstanding the challenges of identifying correctly the diagnosis of OSA and asthma using the MarketScan database, it is well established that the similarities between asthma and OSA in children are quite extensive. Indeed, both are considered inflammatory disorders of the airways as well as low-grade systemic inflammatory diseases [@pmed.1001753-Goldbart1],[@pmed.1001753-Gozal3],[@pmed.1001753-Gogate1]. Asthma and OSA also share risk factors such as allergic rhinitis, obesity, exposure to tobacco smoke, frequent respiratory infections, and African-American race [@pmed.1001753-Prasad1],[@pmed.1001753-Ioachimescu1]. In addition, rhinitis, commonly associated with OSA, is also considered a precursor to asthma [@pmed.1001753-Dixon1]. The association of allergic rhinitis with both OSA and asthma suggests biological plausibility for the idea that OSA is related to asthma, and suggests that in the treatment of OSA, AT potentially improves asthma status by reducing the burden of allergic disease and inflammatory disease of the upper airway. Moreover, the seasonal variation of pediatric OSA is remarkably similar to the seasonal variation of asthma status [@pmed.1001753-VanDole1]--[@pmed.1001753-Gozal4]. Thus, although this study supports an association and by no means confirms causality, there is a rationale to support a biologically plausible link between asthma and adenotonsillar morbidity, namely OSA.

Furthermore, a relatively large number of questionnaire-based studies assessing symptoms of asthma or the presence of snoring have thus far supported the presence of an association between OSA and recurrent wheezing and/or asthma across many regions and states [@pmed.1001753-Desager1],[@pmed.1001753-Verhulst1]--[@pmed.1001753-Chng1]. Notwithstanding the limitations of such questionnaire-based surveys, there appears to be a severity-dependent effect, whereby more severe OSA is associated with poorer asthma control [@pmed.1001753-Ramagopal1]. Although randomized controlled studies are needed to prove cause and effect between OSA and asthma, the present findings provide a compelling argument in favor of such studies, considering the putative improvements that emerged in asthma-related health care utilization following AT.

The current results are supportive of the findings in three previous studies [@pmed.1001753-KheirandishGozal1],[@pmed.1001753-Saito1],[@pmed.1001753-Busino1]. Saito and colleagues [@pmed.1001753-Saito1] reported that in 25 patients with asthma, AT improved asthma symptoms in 88%, with 60% of children able to eliminate all of their asthma therapies, and 28% able to eliminate some of their therapies [@pmed.1001753-Saito1]. In a retrospective study of 93 children with asthma, AT was associated with significant reductions of asthma therapies, including corticosteroids, and with improvements in asthma [@pmed.1001753-Busino1]. Finally, Kheirandish-Gozal and colleagues [@pmed.1001753-KheirandishGozal1] demonstrated in a prospective study that AT for polysomnographically demonstrated OSA was associated with reduced symptoms and rescue inhaler therapy usage in 35 children with poorly controlled asthma, and further reported significant improvements in pulmonary function following AT. However, these three studies included small sample sizes and short follow-up periods that clearly limit their generalizability [@pmed.1001753-KheirandishGozal1],[@pmed.1001753-Saito1],[@pmed.1001753-Busino1]. None of these studies compared children with asthma who underwent AT to a group of children with asthma who did not undergo AT, an important issue since improvements in asthma status seen following AT in these three studies could also be related to seasonal variation, or related to a spontaneous improvement in asthma control over time through growing older [@pmed.1001753-Ko1]. In order to address these limitations, our study included a very large sample of privately insured children with asthma who underwent AT compared to children with asthma who did not undergo AT. Moreover, we took advantage of the MarketScan database, which includes features of health care resource utilization over time for our longitudinal comparisons. Although the database provides information on a large sample of privately insured children, it does not include any data on the large group of uninsured children or those receiving health care services through public health insurance such as Medicaid. On the other hand, our data exclude the confounding effect of lack of access to health care, as all children included in our cohort were privately insured.

Our study has several additional limitations that are primarily inherent to the analysis of large administrative databases. Some of our outcomes were based entirely on physician billing practices. While there is a possibility of coding error or reporting bias, there is no reason to assume that such errors or biases differ among AT+ and AT− children. Furthermore, the inclusion of data on prescription refills as an additional outcome measure in this study provides additional objective outcomes that are not dependent on physician billing practices. As mentioned earlier, the MarketScan database does not provide information regarding the ethnicity of children. The racial disparities regarding health care utilization are very relevant to asthma control [@pmed.1001753-Crocker1],[@pmed.1001753-Blixen1]. In addition, data were not available for obesity status, and therefore we were unable to control for body mass index, another important risk factor in asthma prevalence and severity [@pmed.1001753-FigueroaMunoz1],[@pmed.1001753-Gilliland1]. We acknowledge that race and obesity are important confounding variables for asthma status, and the unavailability of data on both race and obesity status represents an important limitation, particularly with regard to our selection of matching control children with asthma who did not undergo AT. In spite of this limitation, we believe that matching a child\'s home location and geographical state to the level of county of residence---a surrogate of a child\'s socioeconomic status---can serve to minimize any potential discrepancies in race and obesity status between the two groups ([Table 1](#pmed-1001753-t001){ref-type="table"}) [@pmed.1001753-Ewing1]. Although our dataset included children who received services up to 2010, we do not anticipate any change in the association between AT and asthma since 2010.

Notwithstanding the study\'s limitations, using a large sample size of carefully selected children with asthma who underwent AT, we demonstrated that AT was associated with reduced asthma severity and improved control. Moreover, asthma-related outcomes in children after AT were comparable to those in children with asthma who did not undergo AT. While recent evidence reveals that the most common reason for AT in the United States is OSA [@pmed.1001753-Erickson1], it is important to acknowledge that this commonly performed surgery is not without risk. Morbidities can range from relatively minor hemorrhage and dehydration to more severe complications including anoxic brain injury and death [@pmed.1001753-Statham1],[@pmed.1001753-Goldman1].

In summary, our findings provide additional evidence that AT is associated with improved asthma control and suggest that OSA is also associated with the severity of asthma in these children. Further research is needed to better elucidate the pathways linking OSA with asthma in order to establish biological plausibility and, finally, to establish the criteria for identification of those children with asthma most likely to develop OSA and to potentially benefit from AT.
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AAE

:   acute asthma exacerbation

ARER

:   asthma-related emergency room visit

ARH

:   asthma-related hospitalization

ASA

:   acute status asthmaticus

AT

:   adenotonsillectomy

CPT

:   current procedural terminology

ICD-9-CM

:   International Classification of Diseases, Ninth Revision--Clinical Modification

OSA

:   obstructive sleep apnea

[^1]: The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: RB DG BM. Performed the experiments: RB BHC. Analyzed the data: RB BHC BM DG. Contributed reagents/materials/analysis tools: RB BHC. Wrote the first draft of the manuscript: RB. Wrote the paper: RB DG BM. [ICMJE](http://www.icmje.org/) criteria for authorship read and met: RB BHC DG BM. Agree with manuscript results and conclusions: RB BHC DG BM. Collected data: RB BHC BM. Participated in data interpretation and manuscript preparation: RB BHC DG BM. Oversaw all analyses and take full responsibility for the work as a whole, including the study design, access to data, and the decision to submit and publish the manuscript: RB BM. Senior author: BM.
